INHALATION CAPSULES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Inhalation Capsules Market Size and Forecast – 2025 to 2032

The Global Inhalation Capsules Market is estimated to be valued at USD 980.1 Mn in 2024 and is expected to reach USD 1,524.4 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 6.5% from 2025 to 2032. The market's growth is primarily driven by the increasing prevalence of respiratory diseases, such as asthma and chronic obstructive pulmonary disease and the rising demand for efficient drug delivery systems.

Key Takeaways of the Global Inhalation Capsules Market:

• By Product Type, Dry Powder Inhalers (DPIs) are expected to lead the market with a 33.6% share in 2025.
• In terms of Application, Asthma will account for the largest market share of 34.2% in 2025.
• By Patient Group, adults are projected to dominate the market, contributing approximately 60.1% of the share in 2025.
• North America is expected to lead the market, holding a share of 40.3% in. Asia Pacific is anticipated to be the fastest-growing region, with a market share of 25.2% in 2025.

Market Overview:

The inhalation capsules market is witnessing a significant trend towards the development of innovative and advanced drug delivery technologies. Manufacturers are focusing on creating capsules with improved lung deposition, enhanced stability, and better patient compliance. Additionally, there is a growing emphasis on the development of biodegradable and eco-friendly capsule materials to reduce environmental impact. The market is also experiencing a shift towards personalized medicine, with the development of capsules tailored to specific patient needs and requirements.

Currents Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Analysis

To learn more about this report, Request sample copy

Inhalation Capsules Market Insights, By Product Type - Dry powder inhalers dominate driven by ease of use and drug stability

In terms of Product Type, Dry Powder Inhaler segment is expected to contribute the highest market share of 33.6% in 2025. DPIs offer a convenient and effective method of delivering medication directly to the lungs, making them a popular choice among patients and healthcare providers alike.

One of the primary drivers of DPI's market dominance is its ease of use. Unlike other inhalation devices, DPIs do not require coordination between inhalation and actuation, making them suitable for a wide range of patients, including the elderly and those with limited dexterity. The simple operation of DPIs involves inhaling the medication in a single breath, ensuring consistent and reliable drug delivery.

For Instance, In June 2021, Glenmark Pharmaceuticals, harmaceutical company Ltd has launched Tiogiva, a bioequivalent version of Boehringer Ingelheim's Spiriva Handihaler, in the UK. Tiogiva is a Tiotropium Bromide Dry Powder Inhaler (DPI) used for treating chronic obstructive pulmonary disease (COPD). This marks Glenmark as one of the first to offer a bioequivalent DPI in the UK.

Inhalation Capsules Market Insights, By Application - Asthma leads owing to rising global prevalence and need for effective management

In terms of Application, Asthma segment is projected to contribute the highest market share of 34.2% in 2025. Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to symptoms such as wheezing, coughing, and shortness of breath. The increasing prevalence of asthma worldwide has been a major driver for the adoption of inhalation capsules. In May 2024, according to the World Health Organization (WHO), asthma affects over 339 million people globally, with the number expected to rise in the coming years.

This growing patient population has created a substantial demand for effective and convenient asthma management solutions, including inhalation capsules.

Inhalation capsules offer targeted drug delivery directly to the lungs, providing quick relief from asthma symptoms and long-term control of the condition. The ability to deliver medication directly to the site of inflammation reduces systemic exposure and minimizes potential side effects associated with oral or injectable medications. This targeted approach has made inhalation capsules a preferred choice among healthcare providers and patients for managing asthma.

Capsules Market Insights, By Patient Group: Adults dominate due to high respiratory disease burden and treatment adoption

In the global inhalation capsules market, the adults segment is projected to dominate in 2025, accounting for approximately 60.1% of the market share. This dominance is attributed to the high prevalence of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD) among adults, coupled with increased awareness and adoption of inhalation therapies in this demographic.

The convenience and rapid onset of action offered by inhalation capsules make them a preferred choice for adult patients managing chronic respiratory diseases. Furthermore, the adult population's proactive approach to health management and the availability of a wide range of inhalation capsule products tailored to their needs contribute to this segment's leading position.

Regional Insights

To learn more about this report, Request sample copy

North America Inhalation Capsules Market Analysis and Trends

North America dominates the global inhalation capsules market with a share of 40.3% in 2025. The region boasts a well-established healthcare infrastructure, coupled with a high prevalence of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). The presence of major pharmaceutical companies, such as Pfizer, Merck, and GlaxoSmithKline, has further contributed to the market's growth. These companies have made significant investments in research and development, leading to the introduction of innovative inhalation capsule products. Moreover, the region's stringent regulatory framework ensures the safety and efficacy of these products, instilling confidence among healthcare professionals and patients alike.

For instance, in August 2023, Lupin Limited, a global pharmaceutical leader, launched Tiotropium Bromide Inhalation Powder, 18 mcg/capsule in the U.S., a generic version of Boehringer Ingelheim’s Spiriva HandiHaler. This product treats chronic obstructive pulmonary disease (COPD), which affects over 15 million adults in the U.S. Lupin’s launch marks the first FDA-approved generic for Spiriva, aiming to improve healthcare accessibility and support COPD patients.

Asia Pacific Inhalation Capsules Market Analysis and Trends

Asia Pacific is expected to exhibit the fastest growth in the global inhalation capsules market with a share of 25.2% in 2025. The region's rapid economic development, coupled with the rising prevalence of respiratory diseases due to factors such as air pollution and smoking, has fueled the demand for inhalation capsules. Countries like China and India have witnessed a significant increase in healthcare expenditure, leading to improved access to advanced respiratory treatments. The growing geriatric population in the region, which is more susceptible to respiratory ailments, has further contributed to the market's expansion. Additionally, the increasing adoption of generic drugs and the presence of local manufacturers have made inhalation capsules more affordable and accessible to a broader population.

For instance, in December 2024, Alembic Pharmaceuticals Limited, an India-based pharmaceutical company, received the USFDA final approval for its Divalproex Sodium Delayed-Release Capsules USP, 125 mg, a generic equivalent of AbbVie’s Depakote Sprinkle Capsules. Divalproex Sodium is an anti-epileptic drug used for treating complex partial seizures, absence seizures, and multiple seizure types.

Global Inhalation Capsules Market Outlook for Key Countries

U.S. Inhalation Capsules Market Trends

The U.S. market for inhalation capsules is characterized by a strong presence of major pharmaceutical companies, extensive research and development activities, and a robust healthcare infrastructure. The country's high prevalence of respiratory diseases, coupled with an aging population, has driven the demand for innovative inhalation capsule products. Key players such as Pfizer, Merck, and AstraZeneca have been instrumental in shaping the market landscape through their product offerings and collaborations with research institutions.

For instance, in September 2021, Polyphor, a biopharmaceutical company, entered a merger agreement with EnBiotix, a U.S.-based, late-stage clinical company specializing in treatments for rare, chronic respiratory diseases. Under the agreement, Polyphor acquires all EnBiotix shares in exchange for Polyphor stock, with the combined entity set to be renamed and listed under a new ticker.

U.K. Inhalation Capsules Market Trends

The U.K. inhalation capsules market is evolving, driven by rising respiratory disease prevalence, growing preference for plant-based capsules, and advances in dry powder inhaler technologies. Regulatory support, sustainability focus, and the shift towards patient-centric solutions are also shaping the market. These trends reflect the increasing demand for effective, eco-friendly, and accessible drug delivery systems in the U.K.

For instance, on May 1, 2025, 3P innovation, a U.K.-based automation company specializing in high-precision liquid and powder drug filling systems, launched its next-generation dry powder inhaler (DPI) filling technology. Designed as an enhanced equivalent to the original GSK Diskus system—whose patent expired in 2022—this new system offers five times faster filling speeds, improved containment for potent and dusty powders, and the ability to handle complex formulations like magnesium stearate blends.

India Inhalation Capsules Market Trends

India continues to be a key player in the global inhalation capsules market, driven by its large patient pool, increasing healthcare awareness, and growing pharmaceutical industry. The country's generic drug market has played a significant role in making inhalation capsules more affordable and accessible to the masses. Indian pharmaceutical companies, such as Cipla and Lupin, have established a strong presence in the market through their product portfolios and strategic partnerships.

For instance, in December 2024, Cipla Limited, a leading India-based pharmaceutical company, received approval from Central Drugs Standard Control Organisation (CDSCO) to distribute and market Afrezza, an inhalation insulin developed by MannKind, in India. Afrezza is a rapid-acting insulin that offers a non-injectable option for adults with type 1 and type 2 diabetes. It works within 12 minutes by mimicking the body's natural insulin response, enhancing diabetes management accessibility in India.

Japan Inhalation Capsules Market Trends

Japan's market for inhalation capsules is characterized by a high level of technological advancement, strict regulatory standards, and a focus on innovation. The country's aging population and increasing prevalence of respiratory diseases have driven the demand for effective inhalation therapies. Japanese pharmaceutical companies, such as Astellas Pharma and Daiichi Sankyo, have been at the forefront of developing novel inhalation capsule formulations. The market has also benefited from collaborations between academia and industry, fostering research and development activities. Japan's well-established healthcare system and reimbursement policies have further supported the adoption of inhalation capsules in the country.

End user Feedback and Unmet Needs in the Global Inhalation Capsules Market

• End users across the global inhalation capsules market, including healthcare providers, pharmacists, and respiratory therapists, consistently praise the accuracy of dosage delivery, particularly for chronic conditions like asthma and chronic obstructive pulmonary disease. However, significant challenges persist, especially in low-resource settings, where end-users cite limited device compatibility, high costs, and difficulty sourcing matching inhalers, which lead to treatment delays and increased operational burdens.
• The market’s unmet needs revolve around technological gaps (lack of device-agnostic capsules), affordability issues, and inadequate technical support, particularly for healthcare workers in developing regions. Addressing these concerns through innovations such as universal device-compatible capsules, sustainable packaging, and enhanced training programmes could unlock growth opportunities, improve customer retention, and drive market expansion by catering to the diverse and evolving needs of end-users worldwide.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Request sample copy

Key Developments:

• On May 12, 2025, Aptar CSP Technologies, a leading provider of active material science solutions, expanded its cGMP manufacturing capacity in New Jersey for clinical packaging of dry powder inhalation (DPI) capsules using its Activ-Blister technology. The facility will support Phase 1 and 2 trials, offering services like stability studies and clinical supply management.
• In February 2024, Catalent, Inc., a global leader in enabling the development and supply of advanced treatments, expanded its Boston facility’s capabilities for filling potent dry powders into inhalation capsules. The upgrades include spray drying capacity, isolators for potent compounds, cleanroom enhancements, and advanced drum dosing with AMV technology, positioning Catalent as the CDMO with the largest GMP capacity for inhaled powders.
• In March 2024, AstraZeneca, a global biopharmaceutical leader with over 50 years of experience in respiratory care, expanded its U.S. savings programs to cap patient out-of-pocket costs at USD 35 Bn per month for all its inhaled respiratory medicines, including AIRSUPRA, BEVESPI AEROSPHERE, BREZTRI AEROSPHERE, and SYMBICORT. This initiative aims to improve access and affordability for uninsured and underinsured asthma and COPD patients.
• In July 2023, Viatris Inc., a global healthcare company, in partnership with Kindeva Drug Delivery, launched Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol in the U.S. This is the first USFDA-approved generic version of AstraZeneca’s Symbicort® for asthma and COPD. Breyna is available in 80/4.5 mcg and 160/4.5 mcg strengths, providing a cost-effective option for over 16 million COPD patients and 25 million asthma patients in the U.S., supporting Viatris' mission to enhance global healthcare access.

Top Strategies Followed by Global Inhalation Capsules Market Players

• Established Players in the global inhalation capsules market are focusing on extensive research and development to innovate high-performance products. These companies invest heavily in R&D to develop advanced capsule technologies that enhance drug delivery and patient compliance. For instance, leading players are working on developing capsules with improved moisture resistance, better powder flow, and enhanced aerosolization properties. Strategic partnerships with major industry players or original equipment manufacturers (OEMs) are also crucial for established companies to solidify their market presence.
  • For example, Capsugel (a Lonza company) is a leading provider of advanced capsule delivery solutions for pharmaceuticals. Its Zephyr Inhalation Capsules Portfolio is optimized for Dry Powder Inhalers (DPI), offering superior aerosolization and consistent drug delivery. Available in both gelatin and hypromellose (HPMC), Zephyr capsules meet diverse stability and performance needs, supporting efficient and reliable inhalation therapy.

• Mid-level players in the global inhalation capsules market are focusing on delivering cost-effective solutions to target price-sensitive consumers. These companies aim to provide quality products at competitive prices, making inhalation capsules more accessible to a wider patient population. Additionally, mid-level players are actively seeking collaborations with other industry participants to boost their technology, production capabilities, and market presence.
  • In September 2024, Phillips Medisize, a global medical device contract development and manufacturing organisation (CDMO) and a subsidiary of Molex, expanded its inhalation drug delivery expertise through the acquisition of Vectura Group Limited. Vectura, a U.K.-based CDMO, specialises in inhalation device design and formulation, including dry powder inhalers (DPI), metered dose inhalers (MDI), and nebuliser products for both small molecules and biologics.

• Small-scale players in the global inhalation capsules market are adopting niche specialization as a key strategy. These companies target specific market segments with unique features or innovative products. By focusing on niche markets, small-scale players can differentiate themselves from larger competitors and capture a loyal customer base. Qualicaps, a pharmaceutical company, produces hard gelatin capsules specifically designed for inhalation drug delivery, optimised for aerodynamic performance and dose consistency.

Market Report Scope

Inhalation Capsules Market Dynamics

To learn more about this report, Request sample copy

Inhalation Capsules Market - Increasing Prevalence of Respiratory Diseases

The rising prevalence of respiratory diseases worldwide is a significant driver for the growth of the global inhalation capsules market. Chronic respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other pulmonary disorders are becoming increasingly common due to various factors, including air pollution, smoking, and aging populations. As the incidence of these diseases continues to rise, the demand for effective and convenient treatment options, such as inhalation capsules, is expected to grow accordingly. Inhalation capsules offer a targeted and efficient delivery method for medications directly to the lungs, providing quick relief and improved patient compliance. The growing awareness among patients and healthcare professionals about the benefits of inhalation capsules over other forms of medication delivery is further fueling the market growth. Moreover, the increasing healthcare expenditure and improving access to advanced medical treatments in developing countries are expected to contribute to the expanding demand for inhalation capsules in the management of respiratory diseases. For instance, according to the WHO, over 3 million lives are lost to COPD each year, a progressive lung disease affecting over 380 million globally. Often overlooked, COPD is the fourth leading cause of death worldwide. It causes breathing difficulties, cough, and wheezing, primarily due to smoking and air pollution.

Inhalation Capsules Market Opportunity: Rising Demand for Personalized Medicine

The increasing demand for personalized medicine presents a significant opportunity for the global inhalation capsules market. Personalized medicine involves tailoring treatments to individual patients based on their specific genetic, lifestyle, and environmental factors. Inhalation capsules offer a unique advantage in this regard, as they can be customized to deliver precise doses of medication directly to the lungs. By leveraging advancements in capsule technology and drug formulation, manufacturers can develop inhalation capsules that cater to the specific needs of different patient subgroups. This approach can potentially enhance treatment efficacy, reduce side effects, and improve patient outcomes. Moreover, the rising prevalence of respiratory disorders, such as asthma and chronic obstructive pulmonary disease (COPD), coupled with the growing geriatric population, further fuels the demand for personalized inhalation therapies. As healthcare systems increasingly recognize the benefits of personalized medicine, the global inhalation capsules market is poised to capitalize on this opportunity by investing in research and development, collaborating with healthcare providers, and educating patients about the advantages of personalized inhalation therapies.

Analyst Opinion (Expert Opinion)

• The global inhalation capsules market is experiencing robust growth driven by factors such as the rising prevalence of respiratory diseases, technological advancements in drug delivery systems, and increased patient preference for inhalation therapies. Notable industry events like the 6th Annual Inhalation & Respiratory Drug Delivery Hybrid Conference in Prague (2022) and the RESCON Summit in New York (2022) have played pivotal roles in facilitating knowledge-sharing, policy formulation, and showcasing technological innovations within the sector.
• However, the market faces challenges, including the complexity and cost associated with the development and production of inhalation capsules, as well as stringent regulatory hurdles that can delay product approvals. Real-world initiatives, such as Lupin's launch of a generic tiotropium bromide inhalation powder capsule for COPD treatment in the U.S., exemplify efforts to expand market access and address respiratory health needs. Additionally, the growing demand for biosimilar and generic drugs presents opportunities for cost-effective inhalation capsule formulations, increasing accessibility in price-sensitive markets.

Market Segmentation

•  Product Type Insights (Revenue, USD Mn, 2020 - 2032)
  • Dry Powder Inhaler
  • Soft Mist Inhalers
  • Nebulizer Capsules
  • Pressurized Metered-Dose Inhalers
  • Others (Unit-dose vials, disposable nebulizers)
•  Application Insights (Revenue, USD Mn, 2020 - 2032)
  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Bronchitis
  • Pulmonary Fibrosis
  • Cystic Fibrosis
  • Other Respiratory Disorders
•  Patient Group Insights (Revenue, USD Mn, 2020 - 2032)
  • Adults
  • Paediatric
  • Geriatric
•  Gender Insights (Revenue, USD Mn, 2020 - 2032)
  • Male
  • Female
•  Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • GlaxoSmithKline
  • AstraZeneca
  • Boehringer Ingelheim
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries
  • Merck & Co.
  • Mylan N.V.
  • Sun Pharmaceutical Industries
  • Hikma Pharmaceuticals
  • Otsuka Pharmaceutical
  • Chiesi Farmaceutici
  • Cipla
  • AbbVie
  • Sanofi

Sources

Primary Research Interviews:

• Pulmonologists and Respiratory Therapists
• Pharmaceutical Formulation Scientists
• Regulatory Affairs Specialists
• Supply Chain Managers in Pharmaceutical Manufacturing
• Procurement Heads at Hospital Chains and Pharmacies
• Patient Advocacy Groups for Asthma and COPD
• Pharmacovigilance Officers

Databases:

• World Health Organization (WHO) – Global Health Observatory Data Repository
• United Nations Comtrade Database
• US Food and Drug Administration (FDA) – Drugs@FDA, Orange Book
• European Medicines Agency (EMA) – Medicines Data
• National Institute for Health and Care Excellence (NICE), U.K.

Magazines:

• The Pharma Letter
• Pharmaceutical Technology Europe
• Drug Development & Delivery
• Respiratory Therapy Journal
• Pharmaceutical Manufacturing

Journals:

• Journal of Aerosol Medicine and Pulmonary Drug Delivery
• International Journal of Pharmaceutics
• European Journal of Pharmaceutics and Biopharmaceutics
• Journal of Pharmaceutical Sciences
• Respiratory Research

Newspapers:

• The Guardian – Health and Science Section
• The New York Times – Science Section
• Financial Times – Healthcare and Life Sciences Coverage
• The Times of India – Healthcare and Pharma News

Associations:

• International Society for Aerosols in Medicine (ISAM)
• European Respiratory Society (ERS)
• American Thoracic Society (ATS)
• International Pharmaceutical Aerosol Consortium (IPAC-RS)
• Inhaler Group of the International Pharmaceutical Federation (FIP)

Public Domain Sources:

• Google Scholar – Open Access Research Papers
• OpenFDA – US FDA Public APIs
• CORDIS – EU Research and Innovation Projects Database

Proprietary Elements:

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI existing repository of information for last 8 years